Qian Zhang1, Chun-Mei Wang1, Shu-Tian Shi1, Hong Chen1, Yu-Jie Zhou2. 1. Department of Emergency, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. 2. Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China.
Abstract
BACKGROUND: The incidence of left ventricular thrombus (LVT) is 4% to 15% in patients with anterior acute ST-segment elevation myocardial infarction (ant-AMI) in the era of primary percutaneous coronary intervention (PPCI). And patients with LVT have higher in-hospital mortality. HYPOTHESIS: There is a relationship between LVT formation and 1-year major adverse cardio-cerebrovascular events (MACCE) in patients with ant-AMI treated by PPCI. METHODS: Our study population included 1488 consecutive patients with ant-AMI. The primary endpoint was the incidence of MACCE within 1 year after AMI. The secondary endpoint was the thrombosis disappearance. RESULTS: A total of 106 (7.1%) patients were diagnosed with LVT and 1382 (92.9%) patients without LVT. Patients with LVT had a higher incidence of MACCE than in patients without LVT (21.7%vs10.3%; P < 0.001). Univariate analysis showed LVT was associated with an increase in MACCE risk (odds ratio [OR] = 2.40; 95% confidence interval [CI] [1.37-4.21]; P < 0.001). When examining MACCE components individually, LVT was only associated with the incidence of congestive heart failure (OR = 2.41; 95% CI [1.29-4.58]; P = 0.001). After adjustment for principal confounders, LVT remained an independent risk factor for MACCE (HR = 2.28; 95% CI [1.12-6.38]; P = 0.020). Other independent predictors include 24-hour LVEF, creatine kinase peak value, and age. Further analysis found patients with LVT in international normalized ratio (INR) ≥ 2 group had lower MACCE risk and higher thrombus disappearance than in INR < 2 group (13.5%vs29.6%; P = 0.044; 90.4%vs74.1%; P = 0.029). CONCLUSION: For patients with ant-AMI treated by PPCI, LVT is an independent predictor of 1-year MACCE events. Treatment with vitamin K antagonist in the therapeutic range (INR ≥ 2) has the potential to reduce MACCE risk and promote disappearance of thrombus.
BACKGROUND: The incidence of left ventricular thrombus (LVT) is 4% to 15% in patients with anterior acute ST-segment elevation myocardial infarction (ant-AMI) in the era of primary percutaneous coronary intervention (PPCI). And patients with LVT have higher in-hospital mortality. HYPOTHESIS: There is a relationship between LVT formation and 1-year major adverse cardio-cerebrovascular events (MACCE) in patients with ant-AMI treated by PPCI. METHODS: Our study population included 1488 consecutive patients with ant-AMI. The primary endpoint was the incidence of MACCE within 1 year after AMI. The secondary endpoint was the thrombosis disappearance. RESULTS: A total of 106 (7.1%) patients were diagnosed with LVT and 1382 (92.9%) patients without LVT. Patients with LVT had a higher incidence of MACCE than in patients without LVT (21.7%vs10.3%; P < 0.001). Univariate analysis showed LVT was associated with an increase in MACCE risk (odds ratio [OR] = 2.40; 95% confidence interval [CI] [1.37-4.21]; P < 0.001). When examining MACCE components individually, LVT was only associated with the incidence of congestive heart failure (OR = 2.41; 95% CI [1.29-4.58]; P = 0.001). After adjustment for principal confounders, LVT remained an independent risk factor for MACCE (HR = 2.28; 95% CI [1.12-6.38]; P = 0.020). Other independent predictors include 24-hour LVEF, creatine kinase peak value, and age. Further analysis found patients with LVT in international normalized ratio (INR) ≥ 2 group had lower MACCE risk and higher thrombus disappearance than in INR < 2 group (13.5%vs29.6%; P = 0.044; 90.4%vs74.1%; P = 0.029). CONCLUSION: For patients with ant-AMI treated by PPCI, LVT is an independent predictor of 1-year MACCE events. Treatment with vitamin K antagonist in the therapeutic range (INR ≥ 2) has the potential to reduce MACCE risk and promote disappearance of thrombus.
Authors: Nico R Mollet; Steven Dymarkowski; Wim Volders; Jurgen Wathiong; Lieven Herbots; Frank E Rademakers; Jan Bogaert Journal: Circulation Date: 2002-12-03 Impact factor: 29.690
Authors: Monvadi B Srichai; Chelif Junor; L Leonardo Rodriguez; Arthur E Stillman; Richard A Grimm; Michael L Lieber; Joan A Weaver; Nicholas G Smedira; Richard D White Journal: Am Heart J Date: 2006-07 Impact factor: 4.749
Authors: Pasi P Karjalainen; Pekka Porela; Antti Ylitalo; Saila Vikman; Kai Nyman; Mari-Anne Vaittinen; Tuukka J Airaksinen; Matti Niemelä; Tero Vahlberg; K E Juhani Airaksinen Journal: Eur Heart J Date: 2007-01-31 Impact factor: 29.983
Authors: LeRoy Elazar Rabbani; Carol Waksmonski; Sohah N Iqbal; Jennifer Stant; Robert Sciacca; Mark Apfelbaum; Osman R Sayan; James Giglio; Shunichi Homma Journal: J Thromb Thrombolysis Date: 2007-06-12 Impact factor: 2.300
Authors: James L Orford; Panayotis Fasseas; Steven Melby; Kelli Burger; Steven R Steinhubl; David R Holmes; Peter B Berger Journal: Am Heart J Date: 2004-03 Impact factor: 4.749
Authors: Aiham Albaeni; Khaled Chatila; Hind A Beydoun; May A Beydoun; Mohammad Morsy; Wissam I Khalife Journal: Int J Cardiol Date: 2019-07-23 Impact factor: 4.164